JP2013512683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512683A5 JP2013512683A5 JP2012542505A JP2012542505A JP2013512683A5 JP 2013512683 A5 JP2013512683 A5 JP 2013512683A5 JP 2012542505 A JP2012542505 A JP 2012542505A JP 2012542505 A JP2012542505 A JP 2012542505A JP 2013512683 A5 JP2013512683 A5 JP 2013512683A5
- Authority
- JP
- Japan
- Prior art keywords
- mutein
- arg
- sequence
- protein
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010021466 Mutant Proteins Proteins 0.000 claims 9
- 102000008300 Mutant Proteins Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 101150055061 LCN2 gene Proteins 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical class N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000047202 human LCN2 Human genes 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000002184 metal Chemical class 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 239000011616 biotin Chemical class 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 102220515765 cAMP-dependent protein kinase inhibitor alpha_N10D_mutation Human genes 0.000 claims 1
- 239000000824 cytostatic agent Chemical class 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical class C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000003053 toxin Chemical class 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26709809P | 2009-12-07 | 2009-12-07 | |
| US61/267,098 | 2009-12-07 | ||
| PCT/EP2010/069028 WO2011069992A2 (en) | 2009-12-07 | 2010-12-07 | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236010A Division JP6346159B2 (ja) | 2009-12-07 | 2015-12-02 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512683A JP2013512683A (ja) | 2013-04-18 |
| JP2013512683A5 true JP2013512683A5 (OSRAM) | 2013-11-28 |
| JP5913120B2 JP5913120B2 (ja) | 2016-05-11 |
Family
ID=43597993
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542505A Active JP5913120B2 (ja) | 2009-12-07 | 2010-12-07 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
| JP2015236010A Active JP6346159B2 (ja) | 2009-12-07 | 2015-12-02 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
| JP2018099240A Pending JP2018148914A (ja) | 2009-12-07 | 2018-05-24 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
| JP2020117175A Withdrawn JP2021006024A (ja) | 2009-12-07 | 2020-07-07 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
| JP2022106985A Active JP7482544B2 (ja) | 2009-12-07 | 2022-07-01 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236010A Active JP6346159B2 (ja) | 2009-12-07 | 2015-12-02 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
| JP2018099240A Pending JP2018148914A (ja) | 2009-12-07 | 2018-05-24 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
| JP2020117175A Withdrawn JP2021006024A (ja) | 2009-12-07 | 2020-07-07 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
| JP2022106985A Active JP7482544B2 (ja) | 2009-12-07 | 2022-07-01 | 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9549968B2 (OSRAM) |
| EP (3) | EP3660510A3 (OSRAM) |
| JP (5) | JP5913120B2 (OSRAM) |
| KR (2) | KR101974044B1 (OSRAM) |
| CN (1) | CN102770764B (OSRAM) |
| AU (1) | AU2010329995B2 (OSRAM) |
| BR (1) | BR112012013662B1 (OSRAM) |
| CA (1) | CA2779562C (OSRAM) |
| DK (2) | DK2990798T3 (OSRAM) |
| RU (2) | RU2564125C2 (OSRAM) |
| SG (1) | SG10201408073XA (OSRAM) |
| WO (1) | WO2011069992A2 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3230907B2 (ja) | 1993-09-03 | 2001-11-19 | 川崎製鉄株式会社 | 生産性および黒色化に優れた黒色化処理鋼板の製造方法 |
| RU2564125C2 (ru) * | 2009-12-07 | 2015-09-27 | Пирис Аг | Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени |
| DK2606061T3 (da) * | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | Bindingsproteiner til hepcidin |
| EP2809679A1 (en) | 2012-01-31 | 2014-12-10 | Technische Universität München | Muteins of a1m lipocalin and method of production therefor |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EP2925337B1 (en) * | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| RU2723034C2 (ru) | 2014-05-22 | 2020-06-08 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Новые полипептиды со специфическим связыванием и пути их применения |
| WO2016120307A1 (en) | 2015-01-28 | 2016-08-04 | Pieris Ag | Novel proteins specific for angiogenesis |
| EP3064507A1 (en) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| CA2980838A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| SG11201803732PA (en) * | 2015-11-30 | 2018-06-28 | Pieris Australia Pty Ltd | Novel anti-angiogenic fusion polypeptides |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| US20190257832A1 (en) | 2016-07-18 | 2019-08-22 | Philippe Ulsemer | Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors |
| GB201615254D0 (en) * | 2016-09-08 | 2016-11-23 | Ge Healthcare Bio Sciences Ab | Novel Ligand and use thereof |
| CN107403074B (zh) * | 2017-06-09 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种突变蛋白的检测方法及装置 |
| EP3715370A1 (en) * | 2019-03-28 | 2020-09-30 | Technische Universität München | High affinity anticalins directed against human cd98hc |
| CA3127973A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| ATE76311T1 (de) | 1986-08-19 | 1992-06-15 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| ATE299892T1 (de) | 1994-05-18 | 2005-08-15 | Nektar Therapeutics | Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| CA2298439A1 (en) | 1997-08-06 | 1999-02-18 | Zymogenetics, Inc. | Lipocalin homologs |
| US20140080177A1 (en) | 1997-09-26 | 2014-03-20 | Pieris Ag | Anticalins |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| NZ508249A (en) | 1998-06-08 | 2003-02-28 | F | Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US6566073B1 (en) | 1998-10-19 | 2003-05-20 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| CN1279053C (zh) * | 1999-03-04 | 2006-10-11 | 普雷西斯药品公司 | 含有D－氨基酸的β－淀粉样肽聚集的调节因子 |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003275958A1 (en) * | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| US8313924B2 (en) * | 2006-08-01 | 2012-11-20 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| JP5746861B2 (ja) * | 2007-10-19 | 2015-07-08 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | 哺乳動物のｎｇａｌに結合する抗体及びその使用 |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| RU2564125C2 (ru) | 2009-12-07 | 2015-09-27 | Пирис Аг | Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени |
| DK2606061T3 (da) * | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | Bindingsproteiner til hepcidin |
| AU2011331232B2 (en) | 2010-11-15 | 2015-05-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| EP3441400B1 (en) * | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| WO2016120307A1 (en) | 2015-01-28 | 2016-08-04 | Pieris Ag | Novel proteins specific for angiogenesis |
| WO2016131804A1 (en) | 2015-02-18 | 2016-08-25 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2010
- 2010-12-07 RU RU2012128586/10A patent/RU2564125C2/ru active
- 2010-12-07 EP EP19198835.1A patent/EP3660510A3/en not_active Withdrawn
- 2010-12-07 SG SG10201408073XA patent/SG10201408073XA/en unknown
- 2010-12-07 KR KR1020187007781A patent/KR101974044B1/ko active Active
- 2010-12-07 EP EP10784824.4A patent/EP2510357B1/en active Active
- 2010-12-07 RU RU2015137158A patent/RU2707126C2/ru active
- 2010-12-07 AU AU2010329995A patent/AU2010329995B2/en active Active
- 2010-12-07 JP JP2012542505A patent/JP5913120B2/ja active Active
- 2010-12-07 BR BR112012013662-3A patent/BR112012013662B1/pt active IP Right Grant
- 2010-12-07 CA CA2779562A patent/CA2779562C/en active Active
- 2010-12-07 EP EP15186647.2A patent/EP2990798B1/en active Active
- 2010-12-07 CN CN201080055370.5A patent/CN102770764B/zh active Active
- 2010-12-07 US US13/514,133 patent/US9549968B2/en active Active
- 2010-12-07 WO PCT/EP2010/069028 patent/WO2011069992A2/en not_active Ceased
- 2010-12-07 DK DK15186647T patent/DK2990798T3/da active
- 2010-12-07 DK DK10784824.4T patent/DK2510357T3/en active
- 2010-12-07 KR KR1020127017730A patent/KR101842076B1/ko active Active
-
2015
- 2015-12-02 JP JP2015236010A patent/JP6346159B2/ja active Active
-
2016
- 2016-12-15 US US15/380,168 patent/US10618941B2/en active Active
-
2018
- 2018-05-24 JP JP2018099240A patent/JP2018148914A/ja active Pending
-
2020
- 2020-03-06 US US16/812,069 patent/US11827681B2/en active Active
- 2020-07-07 JP JP2020117175A patent/JP2021006024A/ja not_active Withdrawn
-
2022
- 2022-07-01 JP JP2022106985A patent/JP7482544B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512683A5 (OSRAM) | ||
| RU2012128586A (ru) | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ | |
| JP2014502149A5 (OSRAM) | ||
| CN110437320B (zh) | 多肽 | |
| RU2012150766A (ru) | Мутеины липокалина слезы, связывающие альфа il-4 r | |
| AU2012268970B2 (en) | Dimeric binding proteins based on modified ubiquitins | |
| JP2018519802A5 (OSRAM) | ||
| KR20130010461A (ko) | Ｉｌ―２３에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질 | |
| JP2003518075A (ja) | 生理活性化合物の消失半減期延長のための方法及び組成物 | |
| KR20140002657A (ko) | 혈청 알부민에 결합하는 설계된 반복 단백질 | |
| ES2641373T3 (es) | Uso de P3 de proteínas de fusión de bacteriófagos como agentes de unión amiloides | |
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| IL303152A (en) | Compositions and methods for selective depletion of target molecules | |
| JP2019506140A5 (OSRAM) | ||
| AU2012268970A1 (en) | Dimeric binding proteins based on modified ubiquitins | |
| EP3706804B1 (en) | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer | |
| RU2019122482A (ru) | Мутеины липокалина с аффинностью связывания в отношении lag-3 | |
| Kang et al. | Defining how ubiquitin receptors hHR23a and S5a bind polyubiquitin | |
| JPH04503761A (ja) | Ｐａｉ―２の変異体 | |
| WO2023235522A1 (en) | Compositions and methods for selective depletion of egfr target molecules | |
| Vijayasarathy et al. | Cone snail prolyl-4-hydroxylase α-subunit sequences derived from transcriptomic data and mass spectrometric analysis of variable proline hydroxylation in C. amadis venom | |
| JP2007535293A5 (OSRAM) | ||
| CN110078832A (zh) | 一类基于ZZ domain的广谱二抗及其制备方法和应用 | |
| KR102140557B1 (ko) | 단백질-단백질 결합체를 형성 매개 펩타이드 및 이를 이용한 단백질-단백질 결합체 형성 방법 | |
| CN100543034C (zh) | 一种整合酶抑制肽及其在艾滋病药物制备中的应用 |